To test for NQO1 dependence on this enhanced in vivo toxicity, we established xenografts with A549 NOQ1-KO cells in NSG mice and treated them with either KP372-1 treatment alone or with KP372-1 + PARPi combination treatment and observed no enhancement of KP372-1 + rucaparib in tumor killing and no increase in survival (Figure 6C), suggesting that KP372-1 alone or KP372-1 + rucaparib mediated antitumor efficacy is dependent on NQO1 in vivo. Here, NQO1 is linked to neoplasm.